Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced

ORAGENICS INC

ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.
$4.45M public offering closed Sep 2024; total $6M+ raised in 2024 to fund Phase II trial.
Phase II trial planned later 2024, first in Australia then U.S.; evaluates efficacy on symptom reduction and functional recovery.
Appointed Dr. James Kelly as CMO and Dr. William Peacock as CCO in 2024 for clinical oversight.
Partnership with Avance Clinical in May 2024; Australian Regulatory Submission Brochure targeted Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.